Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This is a single center, double-blind, placebo and positive-controlled, randomized, partial
6-way cross-over study to investigate the pharmacodynamics and pharmacokinetics of CEP-26401
(5, 25, and 125 μg) following single-dose administration to healthy male and female subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries